External Reports and Resources
30 May 2025

New to eviQ: Bispecific antibodies (BsAbs)

The eviQ program has developed a comprehensive suite of product-specific protocols, clinical resources and an education module to support health professionals in safely and effectively delivering bispecific antibody (BsAb) therapies. These resources provide guidance on BsAb mechanisms of action, toxicity profiles and management, and key considerations for patient care.

New eviQ Protocols:
  • ID 4366 Melanoma metastatic uveal tebentafusp (Medical Oncology)
  • ID 4454 Non-Hodgkin lymphoma glofitamab and oBINUTUZumab (Haematology & BMT)

More protocols are on the way, check out the Protocols under development page to see what they are working on.

Updated eviQ Clinical resources:
  • ID 3500 Cytokine-release syndrome
  • ID 3834 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • ID 3835 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment tool

New eviQ eLearning: Bispecific antibodies rapid learning

Members are encouraged to join the eviQ team for the launch of their newly developed suite of resources on the management and safe care of patients receiving bispecific antibodies.  The webinar will feature an overview of: The new rapid learning module; Drug-specific protocol updates; Clinical assessment tools to support monitoring and patient care; Guidance on recognising and managing key toxicities, including CRS and ICANS and Protocol-specific patient information resources.

Details: Thu, Jul 03, 12:00 PM - 12:45 PM AEST | Register for 3 July →

Related topics

Toxicity/symptom management
Return to listing